UI Hospitals and Clinics

Clinical Trial Details

Short Title
A Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Official Title

A Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma

Description

Participants in this research study have been diagnosed with angiosarcoma that is unable to be removed by surgery. The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called AMG 386 has on the angiosarcoma. Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. About 41 subjects will take part in this study nationwide. Study treatment will last as long as it is helping the cancer.

Start Date
November 6, 2012
End Date
February 4, 2014
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Clarine Halvorsen, 319-356-3944

Department
Department or Field of Study
Keywords
ALLIANCE A091103 ; AMG 386 ; angiosarcoma ; cancer ; IRB#201209724 ; milhem ; phase 2 ; phase II ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.